{
    "clinical_study": {
        "@rank": "16665", 
        "arm_group": [
            {
                "arm_group_label": "Panel A", 
                "arm_group_type": "Experimental", 
                "description": "Participants will be administered MK-8892 or matching placebo orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 3 mg (Days 15-21), 4 mg (Days 22-28)."
            }, 
            {
                "arm_group_label": "Panel B", 
                "arm_group_type": "Experimental", 
                "description": "Participants will be administered MK-8892 or matching placebo orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), 4 mg (Days 22-28)"
            }, 
            {
                "arm_group_label": "Panel C", 
                "arm_group_type": "Experimental", 
                "description": "Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), 8 mg (Days 22-28)."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety, tolerability, and PK of MK-8892 in participants with\n      pulmonary arterial hypertension. The primary hypothesis is that the geometric mean of\n      MK-8892 area under the concentration time-curve from Hour 0 to 24 hours (AUC0-24hr) in\n      participants with PAH, will be equal to or greater than the efficacious exposure in humans\n      of 0.6 \u03bcM\u2022hr."
        }, 
        "brief_title": "Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Arterial Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  If female, cannot be pregnant or breastfeeding. Females of reproductive potential\n             must agree to agree to use (and/or have their partner use) two (2) acceptable methods\n             of birth control throughout the study and until 2 weeks after the last dose of study\n             drug is administered\n\n          -  Body mass index (BMI) \u226434 kg/m^2 and a total body weight >40 kg (>88 lbs)\n\n          -  Has Group 1 pulmonary hypertension (PAH) as defined by the Dana Point 2008 Clinical\n             Classification including: idiopathic PAH (IPAH), Heritable PAH, Drug and\n             toxin-induced PAH, PAH associated with connective tissue disease or congenital heart\n             disease (repaired simple cardiac defects at least 1 year status post corrective\n             surgery, with no residual intracardiac or extracardiac shunt)\n\n          -  On a stable regimen of background therapy for at least 3 months prior to starting\n             study drug\n\n          -  Have history of right heart catheterization within two years demonstrating pulmonary\n             arterial hypertension\n\n          -  Had pulmonary function testing within one year of starting study medication\n             demonstrating total lung capacity (TLC) >70% predicted, forced expiratory volume in 1\n             second (FEV1) >70% predicted\n\n          -  Have hemoglobin >75% of the lower limit of the normal range\n\n        Exclusion Criteria:\n\n          -  Pulmonary hypertension subtypes including the following according to Dana Point 2008\n             Clinical Classification: human immunodeficiency virus (HIV) infection, portal\n             hypertension, schistosomiasis, chronic hemolytic anemia, persistent pulmonary\n             hypertension of the newborn (PPHN), pulmonary hypertension due to left heart diseases\n             such as systolic dysfunction, diastolic dysfunction or valvular disease, pulmonary\n             hypertension due to lung diseases and/or hypoxia (e.g. chronic obstructive pulmonary\n             disease, interstitial lung disease, other pulmonary diseases with mixed restrictive\n             and obstructive pattern, sleep-disordered breathing, alveolar hypoventilation\n             disorders, chronic exposure to high altitude, and developmental abnormalities),\n             chronic thromboembolic pulmonary hypertension (CTEPH), hematologic disorder\n             (myeloproliferative disorders, splenectomy), systemic disorders (sarcoidosis,\n             pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis, neurofibromatosis,\n             vasculitis), metabolic disorders (glycogen storage disease, Gaucher disease, thyroid\n             disorders) or other disorder (tumoral obstruction, fibrosing mediastinitis, chronic\n             renal failure on dialysis)\n\n          -  Have secondary forms of pulmonary hypertension due to pulmonary veno-occlusive\n             disease (PVOD), or pulmonary capillary hemangiomatosis (PCH)\n\n          -  Resting systolic blood pressure <105 mmHg, or resting heart rate \u2265110/min\n\n          -  Family history of Long QT Syndrome\n\n          -  Uncorrected hypokalemia or hypomagnesemia\n\n          -  Taking medications that are potent inhibitors or inducers of Cytochrome P450 3A4\n             (CYP3A4) including but not limited to cyclosporine, systemic itraconazole or\n             ketoconazole, glyburide, erythromycin, clarithromycin, or telithromycin, nefazodone,\n             protease inhibitors, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin,\n             rifampicin, St John's wort, diltiazem and verapamil) or has discontinued treatment <3\n             weeks prior to the start of the study. Concomitant medications, including\n             anticoagulants, angiotensin converting enzyme (ACE) -inhibitors, diuretics, bosentan,\n             ambrisentan and selected calcium channel blockers (e.g., amlodipine) may be allowed\n             at the discretion of the investigator with the concurrence of the Sponsor.\n\n          -  Unable to refrain from or anticipates the use of organic nitrates (e.g.\n             nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, pentaerythritol)\n             beginning approximately 2 weeks before start of study and throughout the study\n\n          -  Unable to refrain from or anticipates the use of prostanoid therapies beginning\n             approximately 2 weeks before start of study and throughout the study\n\n          -  Consume excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic\n             beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces], wine [125\n             mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day\n\n          -  Major surgery or donated blood within previous 8 weeks\n\n          -  Participated in another investigational study within 4 weeks\n\n          -  History of significant multiple and/or severe allergies\n\n          -  Regular user of illicit drugs, or has a history of drug (including alcohol) abuse,\n             within approximately 6 months\n\n          -  Pregnant or breast-feeding, or expecting to conceive\n\n          -  Interstitial lung disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01926509", 
            "org_study_id": "8892-005", 
            "secondary_id": "2013-002529-51"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Panel A", 
                    "Panel B", 
                    "Panel C"
                ], 
                "intervention_name": "MK-8892", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Panel A", 
                    "Panel B"
                ], 
                "intervention_name": "Placebo for MK-8892", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eran Gefen", 
                    "phone": "38 (044) 393 74 80"
                }, 
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Merck Sharp & Dohme Bulgaria EOOD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "German Medical Information Center", 
                    "phone": "49 800 673 673 673"
                }, 
                "facility": {
                    "address": {
                        "city": "Haar", 
                        "country": "Germany"
                    }, 
                    "name": "Merck Sharp & Dohme GmbH"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Bulgaria", 
                "Germany"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A 28-Day Multiple-Dose Titration Study to Assess the Effects of MK-8892 on Safety, Tolerability and Pharmacokinetics in Subjects With Pulmonary Arterial Hypertension", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Concentration Time-curve from Hour 0 to 24 hours (AUC0-24hr) of MK-8892", 
                "safety_issue": "No", 
                "time_frame": "Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose on Days 1 and 28"
            }, 
            {
                "measure": "Number of Participants Who Had Study Drug Discontinued Due to an Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "up to 28 days"
            }
        ], 
        "removed_countries": {
            "country": "Moldova, Republic of"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01926509"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}